EUCTR2011-002319-27-DE进行中（未招募）1 期
Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy - Phase II study of birch SLIT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who signed and dated the informed consent form obtained prior to any study specific examination
- •Female or male patients between 18 and 65 years of age at the time of signing the informed consent form
- •Patients with moderate-to-severe allergic rhinitis/rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
- •Patients with or without well controlled mild-to-moderate asthma defined in GINA guideline (Global Initiative for Asthma, 2017).
- •Forced expiratory volume (FEV1) in one second > 70 % of predicted normal value (only for asthmatic patients)
- •Sensitization to birch pollen, verified by: positive skin prick test (wheal diameter = 3 mm and negative control < 2 mm and positive (histamine) control = 3 mm) and, Serum allergen-specific IgE to birch = 0.7 kU/L (CAP EAST class = 2) and positive response to nasal provocation with birch pollen allergen extract (at least at the fourth concentration step)
- •Assumed compliance and ability of the patient to understand the patient´s diary and to follow the instructions of the study staff
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 165
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous immunotherapy with tree pollen allergen extracts according to the homologous group of tree pollen of the birch group” / fagales group”, as defined in Annex 1 in the Guideline on allergen products: production and quality issues (EMEA/CHMP/BWP/304831), within the last 5 years
- •Patients with co-sensitizations to any perennial or seasonal allergen with clinical manifestations or co-allergies, whose allergic symptoms interfere with the conduct of the study (e. g. with the tNPT)
- •Simultaneous participation in other clinical trials
- •Simultaneous specific immunotherapy with other allergens
- •Participation in a clinical trial in the last three months before enrolment
- •Asthmatic patients with forced expiratory volume (FEV1) = 70 % of predicted normal value
- •Partly controlled or uncontrolled asthma according to GINA guideline (Global Initiative for Asthma, 2017)
- •Severe acute or chronic inflammatory or infectious diseases
- •Diseases of the immune system such as autoimmune and immune deficiencies (with exception to well controlled Hashimoto thyroiditis and type-1 diabetes mellitus)
- •Chronic or acute diseases of the heart, kidney or liver with severe impairment of their function
- •Hypersensitivity to excipients of the IMP
- •Any severe or unstable lung disease e. g. active tuberculosis, cystic fibrosis, COPD
- •Chronic or severe acute diseases of nose or eyes
- •Irreversible secondary disorders of the target organs (e. g. emphysema, bronchiectasis)
- •Therapy with immunoglobulins
- •Completed or ongoing treatment with anti-IgE-antibody
- •Malignancy within the previous 5 years
- •Alcohol, drug, or medication abuse within the past year and/or during the study
- •Use of non-allowed medication (see section 5.3.1)
- •Contraindications for SPT
- •Contraindications for NPT
- •Relationship or dependence with the sponsor and/or investigator
- •Legal incapacity
- •Patients who are jurisdictional or governmentally institutionalized
- •Serious systemic reactions to allergen-specific immunotherapy in the past
- •Active chronic urticaria
- •Active severe atopic eczema
- •Existing or intended pregnancy, lactation or inadequate contraceptive measures for woman with child-bearing potential or a positive pregnancy test at screening
- •Severe psychiatric, psychological, or neurological disorders; completed or ongoing long-term treatment with tranquilizers or psychactive drugs (including tricyclic antidepressants)
- •Risk of non-compliance by the patient with study procedures
研究者
相似试验
进行中（未招募）
1 期
Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergyEUCTR2021-002881-42-DEROXALL Medizin GmbH200
进行中（未招募）
1 期
Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergyAllergic rhinitis / rhino-conjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 20.0Level: LLTClassification code 10020419Term: House dust mite allergySystem Organ Class: 100000004870MedDRA version: 21.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisSystem Organ Class: 100000004855EUCTR2011-002317-10-DEROXALL Medizin GmbH165
进行中（未招募）
1 期
Phase II study to assess the tolerability, safety and efficacy ofsubcutaneous cluster-immunotherapy in patients suffering from birchpollen allergyEUCTR2011-002296-42-DEROXALL Medizin GmbH165
进行中（未招募）
2 期
A clinical trial to study the effects of two drugs, Folfox and CT-011 in patients with cancer of large intestine.CTRI/2014/08/004922CureTech Ltd171
进行中（未招募）
1 期
Study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastaticmelanomaEUCTR2011-004501-24-GBCureTech Ltd.100